Scarica l'app Stockscreener
39.01
0.10%
-0.04
Dopo l'orario di chiusura:
39.17
0.16
+0.41%
10 X Genomics Inc Borsa (TXG) Ultime notizie
Piper Sandler raises 10X Genomics stock price target on clinical pivot - Investing.com UK
10x Genomics stock hits 52-week high at 37.58 USD - Investing.com
Spatial Genomics and Transcriptomics Market Size to Reach USD 1.90 Billion by 2035, Growing at a 12.23% CAGR | SNS Insider - GlobeNewswire Inc.
10x Genomics, Inc.(NasdaqGS:TXG) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
10x Genomics Inc Class A Actuals & Estimates (FWB:1KJ) - TradingView
1KJ Forecast — Price Target — Prediction for 2027 - TradingView
10x Genomics Inc Class A Actuals & Estimates (DUS:1KJ) - TradingView
Stocks making big moves this week: Qualcomm, Accenture, 10x Genomics, Seagate, and Lattice Semiconductor - Yahoo Finance
Price to earnings forward of 10x Genomics, Inc. – NASDAQ:TXG - TradingView
10x Genomics Inc Class A Actuals & Estimates (MUN:1KJ) - TradingView
Enterprise value to revenue forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10x Genomics Inc Class A Actuals & Estimates (NASDAQ:TXG) - TradingView
Enterprise value to EBIT forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10X Genomics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
10x Genomics Inc Class A Actuals & Estimates (LSE:0A88) - TradingView
Enterprise value to EBITDA forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10x Genomics Inc Class A Actuals & Estimates (BIVA:TXG) - TradingView
Price to sales forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
TXG Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10x genomics CEO Serge Saxonov sells $1.03m in stock By Investing.com - Investing.com Australia
Form 4 10X Genomics Inc For: 24 June By Investing.com - Investing.com Australia
10x genomics CEO Serge Saxonov sells $1.03m in stock - Investing.com
10x Genomics Insider Sold Shares Worth $1,033,269, According to a Recent SEC Filing - marketscreener.com
10x Genomics (TXG) CEO sells 30,000 shares under 10b5-1 plan - Stock Titan
Why Is 10x Genomics (TXG) Stock Soaring Today - Yahoo Finance
Price to book forward of 10x Genomics, Inc. – NASDAQ:TXG - TradingView
10X Genomics Inc (TXG) Institutional Confidence - TradingKey
10X Genomics stock hits 52-week high at 36.0 USD By Investing.com - Investing.com Australia
10X Genomics stock hits 52-week high at 36.0 USD - Investing.com
10x Genomics (TXG): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
10x Genomics boosts single cell proteomics with acquisition of Proteintech Genomics - SelectScience
Insider Sell: Shehnaaz Suliman Sells Shares of 10x Genomics Inc (TXG) - GuruFocus
10x Genomics (TXG) director Suliman sells 5,723 shares in Rule 10b5-1 trades - Stock Titan
TXG - Finviz
10x Genomics Expands Oncology Diagnostics Ambitions Through Cleveland Clinic Collaboration - BioPharma APAC
10X Genomics stock rises on Cleveland Clinic partnership - Investing.com
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer - BioSpace
10x Genomics (TXG) Partners with Cleveland Clinic for Bladder Ca - GuruFocus
10x Genomics and Cleveland Clinic Collaborate to Advance Researc - GuruFocus
10X Genomics (TXG) Stock Surges 4% Following Cleveland Clinic Bladder Cancer Research Agreement - Blockonomi
10x Genomics, Inc and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer - marketscreener.com
10X Genomics stock rises on Cleveland Clinic partnership By Investing.com - Investing.com India
10x Genomics partners with Cleveland Clinic on bladder cancer study By Investing.com - Investing.com Nigeria
10x Genomics partners with Cleveland Clinic on bladder cancer study - Investing.com
10X Genomics Inc (TXG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
10X Genomics Inc (TXG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
10X Genomics Inc (TXG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
10X Genomics Inc (TXG) Valuation: PE, PB & Fair Value Analysis - TradingKey
10X Genomics Inc (TXG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
10x Genomics, Cleveland Clinic study aims to predict bladder cancer treatment response - Stock Titan
10X Genomics Inc (TXG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
10X Genomics Inc (TXG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
10X Genomics Inc (TXG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TXG Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
TXG (Nasdaq) RSU vesting entries listed on Form 144 with JP Morgan intermediary - Stock Titan
Human Cell Atlas leader’s tie to 10x Genomics raises conflict-of-interest questions - statnews.com
10x Genomics’ Growth Prospects Brightened by Strategic Advances - timothysykes.com
9.47%
1.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):